Home > Neurology > EAN 2019 > Migraine > Atogepant efficacious, safe, and well-tolerated for migraine prevention

Atogepant efficacious, safe, and well-tolerated for migraine prevention

Conference
EAN 2019
In a phase 2b/3 trial the efficacy, safety, and tolerability of atogepant vs placebo for prevention of episodic migraine were evaluated. The results of this novel, oral CGRP receptor antagonist indicate that atogepant can be an effective and safe migraine treatment for patients who experience <15 headache days per month. In this multicentre, double-blind, placebo-controlled, parallel-group trial, 834 adult migraine patients, with or without aura, and with 4-14 migraine days in the 28-day baseline period, were randomised 2:1:2:1:2:1 to 12 weeks of treatment with placebo, atogepant 10 mg once-daily, 30 mg once-daily, 30 mg twice-daily, 60 mg once-daily, or 60 mg twice-daily, respectively. Mean baseline monthly migraine days (MMDs) were 7.67. Reductions from baseline in the mean MMD for all 5 atogepant treatment groups were statistically significant compared with reductions in the placebo group after 12 weeks. Mean change in MMDs was for placebo: -2...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on